• Natera will attend the American Transplant Congress on June 20-24, 2026, with 21 scientific presentations focused on its Prospera dd-cfDNA transplant test.
• PEDAL kidney data in 346 biopsy-negative patients showed 18.2% had positive Prospera results, linked to higher adverse outcomes, including >6x graft loss.
• ProActive analysis of 989 kidney recipients found dd-cfDNA donor-fraction <0.5% tied to ~12x lower odds of future rejection, ~5.5x lower odds of graft loss.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Natera Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20260618969671) on June 18, 2026, and is solely responsible for the information contained therein.